Non-abstinent treatment outcomes for cannabis use disorder.
Abstinence remains a standard outcome for potential treatment interventions for Cannabis Use Disorder (CUD). However, there needs to be validation of non-abstinent outcomes. This study explores reductions in self-reported days of use as another viable outcome measure using data from three completed randomized placebo-controlled clinical trials of pharmacological interventions for CUD. The three trials tested the effect of quetiapine (QTP, n 113) dronabinol (DRO, n 156) and lofexidine dronabinol (LFD, n 122). Self-reported cannabis use was categorized into three use-groupsweek heavy (5-7 daysweek), moderate (2-4 daysweek) and light use (0-1 daysweek). Multinomial logistic regressions analyzed the treatment by time effect on the likelihood of light and moderate use compared to heavy use in each study. Across the three trials, there was no significant overall time-by-treatment interaction (QTP p .06 DRO p .15 LFD p .21). However, the odds of moderate compared to heavy use were significantly higher in treatment than in placebo groups starting around the midpoint of each trial. No treatment differences were found between the odds of light compared to heavy use. While study-end abstinence rates have been a standard treatment outcome for CUD trials, reduction from heavy to moderate use has not been standardly assessed. During the last several weeks of each trial, those on active medication were more likely to move from heavy to moderate use, which suggests that certain medications may be more impactful than previously assessed. Future studies should determine if this pattern is associated with less CUD severity andor improved quality of life.